Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine

<p>Abstract</p> <p>Background</p> <p>Patients with HIV infection are at risk of co-infection with HBV, as the routes of transmission are shared and thus immunization with HBV vaccine could be protective in them. The aim of the present study was to assess the efficacy of...

Full description

Bibliographic Details
Main Authors: Singh Haqeeqat, Saikia Biman, Minz Ranjana W, Sud Archana, Arora Sunil K, Singh Surjit, Chawla Yogesh, Datta Usha, Pasricha Neelam, James Isaac, Sehgal Shobha
Format: Article
Language:English
Published: BMC 2006-03-01
Series:BMC Infectious Diseases
Online Access:http://www.biomedcentral.com/1471-2334/6/65
id doaj-97ab29f3aa324826a0afaae2a0c73d81
record_format Article
spelling doaj-97ab29f3aa324826a0afaae2a0c73d812020-11-25T03:23:09ZengBMCBMC Infectious Diseases1471-23342006-03-01616510.1186/1471-2334-6-65Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccineSingh HaqeeqatSaikia BimanMinz Ranjana WSud ArchanaArora Sunil KSingh SurjitChawla YogeshDatta UshaPasricha NeelamJames IsaacSehgal Shobha<p>Abstract</p> <p>Background</p> <p>Patients with HIV infection are at risk of co-infection with HBV, as the routes of transmission are shared and thus immunization with HBV vaccine could be protective in them. The aim of the present study was to assess the efficacy of recombinant vaccine in treatment-naive HIV positive patients and healthy controls, and to dissect out differences if any, in different limbs of immune response.</p> <p>Methods</p> <p>Forty HIV positive patients and 20 HIV negative controls, negative for HBsAg, HBsAbs and HBcAbs were vaccinated with three doses of 40μg and 20μg of vaccine respectively. Patients were divided into high CD4 and low CD4 group based on CD4+ lymphocytes of 200 and < 200/mm3 respectively. Group II consisted of healthy controls. Detection of phenotypic markers was done by flowcytometry. Cytokine estimation was done by sandwich ELISA. HBsAbs were estimated in serum by ELISA.</p> <p>Results</p> <p>After vaccination, CD<sub>4</sub>+, CD<sub>8</sub>+ and CD<sub>3</sub>+ cells increased significantly in all the groups. There was no increase in NK cell activity in patients with high CD<sub>4</sub>+ lymphocytes and only a marginal increase in patients with low CD<sub>4</sub>+ lymphocytes (170 to 293/mm3) whereas a marked increase was observed in controls (252 to 490/mm3). After vaccination, although an increase in memory cells was observed in HIV positive patients, yet HBsAb levels were significantly lower than controls (P < 0.05) indicating a functional defect of memory cells in HIV/AIDS patients. Basal IFN-γ levels were also significantly lower in HIV/AIDS patients (P < 0.01). Although the levels increased after vaccination, the peak level remained lower than in controls. HBsAb titers were much lower in HIV positive patients compared to controls. (High CD<sub>4</sub>+ group: 8834 mIU/ml, low CD<sub>4</sub>+ group: 462 mIU/ml Vs. Controls: 16,906 mIU/ml). IL-4 and IL-10 were low in patients.</p> <p>Conclusion</p> <p>Despite a double dose in patients, IL-4 and IL-10, which regulate antibody response, were also lower in patients, and this together with low CD<sub>4</sub>+ counts and lack of T help, accounted for low HBsAb levels. Vaccination in patients with CD<sub>4</sub>+ lymphocytes < 50/mm<sup>3</sup> was ineffective. Thus early immunization is advocated in all HIV positive patients at a stage when they are still capable of mounting an adequate immune response</p> http://www.biomedcentral.com/1471-2334/6/65
collection DOAJ
language English
format Article
sources DOAJ
author Singh Haqeeqat
Saikia Biman
Minz Ranjana W
Sud Archana
Arora Sunil K
Singh Surjit
Chawla Yogesh
Datta Usha
Pasricha Neelam
James Isaac
Sehgal Shobha
spellingShingle Singh Haqeeqat
Saikia Biman
Minz Ranjana W
Sud Archana
Arora Sunil K
Singh Surjit
Chawla Yogesh
Datta Usha
Pasricha Neelam
James Isaac
Sehgal Shobha
Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine
BMC Infectious Diseases
author_facet Singh Haqeeqat
Saikia Biman
Minz Ranjana W
Sud Archana
Arora Sunil K
Singh Surjit
Chawla Yogesh
Datta Usha
Pasricha Neelam
James Isaac
Sehgal Shobha
author_sort Singh Haqeeqat
title Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine
title_short Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine
title_full Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine
title_fullStr Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine
title_full_unstemmed Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine
title_sort immune responses in patients with hiv infection after vaccination with recombinant hepatitis b virus vaccine
publisher BMC
series BMC Infectious Diseases
issn 1471-2334
publishDate 2006-03-01
description <p>Abstract</p> <p>Background</p> <p>Patients with HIV infection are at risk of co-infection with HBV, as the routes of transmission are shared and thus immunization with HBV vaccine could be protective in them. The aim of the present study was to assess the efficacy of recombinant vaccine in treatment-naive HIV positive patients and healthy controls, and to dissect out differences if any, in different limbs of immune response.</p> <p>Methods</p> <p>Forty HIV positive patients and 20 HIV negative controls, negative for HBsAg, HBsAbs and HBcAbs were vaccinated with three doses of 40μg and 20μg of vaccine respectively. Patients were divided into high CD4 and low CD4 group based on CD4+ lymphocytes of 200 and < 200/mm3 respectively. Group II consisted of healthy controls. Detection of phenotypic markers was done by flowcytometry. Cytokine estimation was done by sandwich ELISA. HBsAbs were estimated in serum by ELISA.</p> <p>Results</p> <p>After vaccination, CD<sub>4</sub>+, CD<sub>8</sub>+ and CD<sub>3</sub>+ cells increased significantly in all the groups. There was no increase in NK cell activity in patients with high CD<sub>4</sub>+ lymphocytes and only a marginal increase in patients with low CD<sub>4</sub>+ lymphocytes (170 to 293/mm3) whereas a marked increase was observed in controls (252 to 490/mm3). After vaccination, although an increase in memory cells was observed in HIV positive patients, yet HBsAb levels were significantly lower than controls (P < 0.05) indicating a functional defect of memory cells in HIV/AIDS patients. Basal IFN-γ levels were also significantly lower in HIV/AIDS patients (P < 0.01). Although the levels increased after vaccination, the peak level remained lower than in controls. HBsAb titers were much lower in HIV positive patients compared to controls. (High CD<sub>4</sub>+ group: 8834 mIU/ml, low CD<sub>4</sub>+ group: 462 mIU/ml Vs. Controls: 16,906 mIU/ml). IL-4 and IL-10 were low in patients.</p> <p>Conclusion</p> <p>Despite a double dose in patients, IL-4 and IL-10, which regulate antibody response, were also lower in patients, and this together with low CD<sub>4</sub>+ counts and lack of T help, accounted for low HBsAb levels. Vaccination in patients with CD<sub>4</sub>+ lymphocytes < 50/mm<sup>3</sup> was ineffective. Thus early immunization is advocated in all HIV positive patients at a stage when they are still capable of mounting an adequate immune response</p>
url http://www.biomedcentral.com/1471-2334/6/65
work_keys_str_mv AT singhhaqeeqat immuneresponsesinpatientswithhivinfectionaftervaccinationwithrecombinanthepatitisbvirusvaccine
AT saikiabiman immuneresponsesinpatientswithhivinfectionaftervaccinationwithrecombinanthepatitisbvirusvaccine
AT minzranjanaw immuneresponsesinpatientswithhivinfectionaftervaccinationwithrecombinanthepatitisbvirusvaccine
AT sudarchana immuneresponsesinpatientswithhivinfectionaftervaccinationwithrecombinanthepatitisbvirusvaccine
AT arorasunilk immuneresponsesinpatientswithhivinfectionaftervaccinationwithrecombinanthepatitisbvirusvaccine
AT singhsurjit immuneresponsesinpatientswithhivinfectionaftervaccinationwithrecombinanthepatitisbvirusvaccine
AT chawlayogesh immuneresponsesinpatientswithhivinfectionaftervaccinationwithrecombinanthepatitisbvirusvaccine
AT dattausha immuneresponsesinpatientswithhivinfectionaftervaccinationwithrecombinanthepatitisbvirusvaccine
AT pasrichaneelam immuneresponsesinpatientswithhivinfectionaftervaccinationwithrecombinanthepatitisbvirusvaccine
AT jamesisaac immuneresponsesinpatientswithhivinfectionaftervaccinationwithrecombinanthepatitisbvirusvaccine
AT sehgalshobha immuneresponsesinpatientswithhivinfectionaftervaccinationwithrecombinanthepatitisbvirusvaccine
_version_ 1724607428933189632